IL-12 is a heterodimeric cytokine comprised of p35 and p40 subunits. IL-12 plays a central role in cell-mediated immunity, promoting the differentiation of CD4+ T cells to the Th1 subset and of CD8+ T cells into mature cytotoxic T lymphocytes (CTLs). IL-12 is a potent stimulator of Natural Killer cells. IL-12 therapy has been suggested as a method of enhancing cytocidal anti-tumour immune responses.
| Inventor | Institute |
|---|---|
| Rosemonde Banks | University of Leeds |
| SKU: | 151023 |
|---|---|
| Product description: | IL-12 is a heterodimeric cytokine comprised of p35 and p40 subunits. IL-12 plays a central role in cell-mediated immunity, promoting the differentiation of CD4+ T cells to the Th1 subset and of CD8+ T cells into mature cytotoxic T lymphocytes (CTLs). IL-12 is a potent stimulator of Natural Killer cells. IL-12 therapy has been suggested as a method of enhancing cytocidal anti-tumour immune responses. |
| Alternate name: | Interleukin 12; Cytotoxic Lymphocyte Maturation Factor 4 KDa Subunit; NK Cell Stimulatory Factor Chain; Interleukin-12 Beta Chain; IL-12 Subunit P4; CLMF P4; NKSF2; Natural Killer Cell Stimulatory Factor; IL12; Subunit P4; Interleukin 12; CLMF2; IMD29; NKSF; P4 |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Recombinant human IL-12 produced by baculovirus. |
| Immunogen Uniprot ID: | P29459 |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 151023 |
|---|---|
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | ELISA ; IHC ; Fn ; RIA ; WB |
| Target: | Interleukin-12 (IL12) p40 subunit |
| Reactivity: | Human |
| Clone: | 1-1D5 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | IL-12 is a heterodimeric cytokine comprised of p35 and p40 subunits. IL-12 plays a central role in cell-mediated immunity, promoting the differentiation of CD4+ T cells to the Th1 subset and of CD8+ T cells into mature cytotoxic T lymphocytes (CTLs). IL-12 is a potent stimulator of Natural Killer cells. IL-12 therapy has been suggested as a method of enhancing cytocidal anti-tumour immune responses. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | ‘-15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Carter et al. 1997. Hybridoma. 16(4):363-9. PMID: 9309427. Production and characterization of monoclonal antibodies to human interleukin-12. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-Integrins aL, aX, aMb2 [24] |
Key Info
Anti-Integrins aL, aX, aMb2 [24]
|
View Tool | |||||||||||||||||||
| 151041 | Anti-LewisX [28] |
Key Info
Anti-LewisX [28]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.